CONTEXT: First-degree relatives of patients with type 2 diabetes (FH+) have been shown to have decreased energy expenditure and decreased expression of mitochondrial genes in skeletal muscle. In previous studies, it has been difficult to distinguish whether mitochondrial dysfunction and differential regulation of genes are primary (genetic) or due to reduced physical activity, obesity, or other correlated factors. OBJECTIVE: The aim of this study was to investigate whether mitochondrial dysfunction is a primary defect or results from an altered metabolic state. DESIGN: We compared gene expression in skeletal muscle from 24 male subjects with FH and 26 without FH matched for age, glucose tolerance, VO(2peak) (peak oxygen uptake), and body mass index using microarrays. Additionally, type fiber composition, mitochondrial DNA content, and citrate synthase activity were measured. The results were followed up in an additional cohort with measurements of in vivo metabolism. RESULTS: FH+ vs. FH- subjects showed reduced expression of mitochondrial genes (P = 2.75 × 10(-6)), particularly genes involved in fatty acid metabolism (P = 4.08 × 10(-7)), despite similar mitochondrial DNA content. Strikingly, a 70% reduced expression of the monoamine oxidase A (MAOA) gene was found in FH+ vs. FH- individuals (P = 0.0009). Down-regulation of the genes involved in fat metabolism was associated with decreased in vivo fat oxidation and increased glucose oxidation examined in an additional cohort of elderly men. CONCLUSIONS: These results suggest that genetically altered fatty acid metabolism predisposes to type 2 diabetes and propose a role for catecholamine-metabolizing enzymes like MAOA in the regulation of energy metabolism.
CONTEXT: First-degree relatives of patients with type 2 diabetes (FH+) have been shown to have decreased energy expenditure and decreased expression of mitochondrial genes in skeletal muscle. In previous studies, it has been difficult to distinguish whether mitochondrial dysfunction and differential regulation of genes are primary (genetic) or due to reduced physical activity, obesity, or other correlated factors. OBJECTIVE: The aim of this study was to investigate whether mitochondrial dysfunction is a primary defect or results from an altered metabolic state. DESIGN: We compared gene expression in skeletal muscle from 24 male subjects with FH and 26 without FH matched for age, glucose tolerance, VO(2peak) (peak oxygen uptake), and body mass index using microarrays. Additionally, type fiber composition, mitochondrial DNA content, and citrate synthase activity were measured. The results were followed up in an additional cohort with measurements of in vivo metabolism. RESULTS: FH+ vs. FH- subjects showed reduced expression of mitochondrial genes (P = 2.75 × 10(-6)), particularly genes involved in fatty acid metabolism (P = 4.08 × 10(-7)), despite similar mitochondrial DNA content. Strikingly, a 70% reduced expression of the monoamine oxidase A (MAOA) gene was found in FH+ vs. FH- individuals (P = 0.0009). Down-regulation of the genes involved in fat metabolism was associated with decreased in vivo fat oxidation and increased glucose oxidation examined in an additional cohort of elderly men. CONCLUSIONS: These results suggest that genetically altered fatty acid metabolism predisposes to type 2 diabetes and propose a role for catecholamine-metabolizing enzymes like MAOA in the regulation of energy metabolism.
Authors: Blair E Warren; Phing-How Lou; Eliana Lucchinetti; Liyan Zhang; Alexander S Clanachan; Andreas Affolter; Martin Hersberger; Michael Zaugg; Hélène Lemieux Journal: Am J Physiol Endocrinol Metab Date: 2014-01-14 Impact factor: 4.310
Authors: C Ekman; T Elgzyri; K Ström; P Almgren; H Parikh; Marloes Dekker Nitert; T Rönn; Fiona Manderson Koivula; C Ling; Å B Tornberg; P Wollmer; K F Eriksson; L Groop; O Hansson Journal: J Appl Physiol (1985) Date: 2015-09-03
Authors: Tina Rönn; Petr Volkov; Cajsa Davegårdh; Tasnim Dayeh; Elin Hall; Anders H Olsson; Emma Nilsson; Asa Tornberg; Marloes Dekker Nitert; Karl-Fredrik Eriksson; Helena A Jones; Leif Groop; Charlotte Ling Journal: PLoS Genet Date: 2013-06-27 Impact factor: 5.917
Authors: Petr Volkov; Anders H Olsson; Linn Gillberg; Sine W Jørgensen; Charlotte Brøns; Karl-Fredrik Eriksson; Leif Groop; Per-Anders Jansson; Emma Nilsson; Tina Rönn; Allan Vaag; Charlotte Ling Journal: PLoS One Date: 2016-06-20 Impact factor: 3.240
Authors: Michal Koc; Michaela Šiklová; Veronika Šrámková; Marek Štěpán; Eva Krauzová; Vladimír Štich; Lenka Rossmeislová Journal: Front Endocrinol (Lausanne) Date: 2021-02-15 Impact factor: 5.555
Authors: Sarah Keildson; Joao Fadista; Claes Ladenvall; Åsa K Hedman; Targ Elgzyri; Kerrin S Small; Elin Grundberg; Alexandra C Nica; Daniel Glass; J Brent Richards; Amy Barrett; James Nisbet; Hou-Feng Zheng; Tina Rönn; Kristoffer Ström; Karl-Fredrik Eriksson; Inga Prokopenko; Timothy D Spector; Emmanouil T Dermitzakis; Panos Deloukas; Mark I McCarthy; Johan Rung; Leif Groop; Paul W Franks; Cecilia M Lindgren; Ola Hansson Journal: Diabetes Date: 2013-12-04 Impact factor: 9.461
Authors: Niko S Wasenius; Bo A Isomaa; Bjarne Östman; Johan Söderström; Björn Forsén; Kaj Lahti; Liisa Hakaste; Johan G Eriksson; Leif Groop; Ola Hansson; Tiinamaija Tuomi Journal: BMJ Open Diabetes Res Care Date: 2020-11